Kaien Health, an A-share listed company, has layout in exosome therapy, with business directions including pet health and anti-aging.

GateUser-bd883c58 · 2026-03-16T03:53:25+00:00

CCTV's "3·15" Gala exposed chaos in exosome cosmetic procedures, drawing attention. The National Medical Products Administration has solicited opinions on pharmaceutical regulation, but exosomes remain in the research stage and have not been approved for market launch. Kenen Health stated it will utilize exosome technology to delay pet aging.

GateUser-bd883c58

2026-03-16 03:53:25

Abstract generation in progress

Beijing Business Daily (Reporter Ding Ning) — On the evening of March 15, CCTV’s “3.15” Gala exposed chaos in the exosome medical beauty industry, bringing unprecedented attention to exosomes. It is understood that the National Medical Products Administration has issued a draft for public comment on including exosomes under drug regulation. However, exosomes are still in the research stage within the medical community, and their mechanisms and clinical effects are not yet clear. Currently, China has not approved any exosome drugs for market sale.

Kaineng Health, a listed company on the A-share market, previously stated on the investor interaction platform that its wholly owned subsidiary, Hainan Kaineng Cells, acquired Laisen’s original business focus, which includes pet health and anti-aging. The goal is to use advanced biotechnologies such as stem cell therapy, NK cell activation, exosome therapy, and NMN supplements to delay pet aging, boost immunity, and improve health conditions.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.